Audentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT132 to Treat X-Linked Myotubular Myopathy

Preliminary data from ASPIRO, the ongoing Phase 1/2 Clinical Study of AT132, expected in fourth quarter of 2017

SAN FRANCISCO, October 3, 2017 / PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Clinical Trial Authorisation (CTA) application for AT132, the Company's gene therapy product candidate being developed to treat X-Linked Myotubular Myopathy (XLMTM). This is the first European CTA approval for the AT132 program, and it allows Audentes to initiate work with clinical study sites in the United Kingdom to enroll patients into ASPIRO, the ongoing Phase 1/2 clinical study of AT132. Preliminary data from ASPIRO is expected to be available in the fourth quarter of 2017.

"This CTA approval represents another important milestone for our AT132 program," stated Matthew R. Patterson, President and Chief Executive Officer. "We recently announced dosing of the first patient in ASPIRO at a U.S. clinical study site, and we are pleased to be working closely with the European XLMTM community as we continue to execute on our global plans to develop AT132 as a potentially transformative product to treat this devastating rare disease."

In addition to ASPIRO, the clinical development program for AT132 includes RECENSUS, a retrospective medical chart review, and INCEPTUS, a prospective natural history run-in study. Audentes has recently presented data from both the RECENSUS and INCEPTUS studies which confirm and expand upon the understanding of the significant disease burden of XLMTM on patients, families and the healthcare system.

About AT132 for X-Linked Myotubular Myopathy

AT132 is the Audentes product candidate being developed to treat XLMTM, a rare monogenic disease characterized by extreme muscle weakness, respiratory failure and early death, with an estimated 50% mortality rate by 18 months of age. XLMTM is caused by mutations in the MTM1 gene, which encodes a protein called myotubularin. Myotubularin plays an important role in the development, maintenance and function of skeletal muscle cells. AT132 is comprised of an AAV8 vector containing a functional copy of the MTM1 gene. Multiple studies in animal models of XLMTM have demonstrated that a single administration of AT132 improved disease symptoms and survival rates, with no significant AT132-related adverse events or safety findings. In one study these effects have lasted more than four and a half years to date. Audentes is developing AT132 in collaboration with Genethon (www.genethon.fr).

About ASPIRO, the Phase 1/2 Clinical Study of AT132

ASPIRO is designed as a multicenter, multinational, open-label, ascending dose study to evaluate the safety and preliminary efficacy of AT132 in approximately 12 XLMTM patients less than five years of age. The study is expected to include nine AT132 treated subjects and three delayed-treatment concurrent control subjects. Primary endpoints include safety (adverse events and certain laboratory measures) and efficacy (assessments of neuromuscular and respiratory function). Secondary endpoints include the burden of disease and health related quality-of-life, and muscle tissue histology and biomarkers. The primary efficacy analysis is expected to be conducted at 12 months, with interim evaluations expected to be conducted at earlier time points. After the primary 12-month assessment, subjects are expected to

be followed for another four years to assess long term safety, durability of effect and developmental progression.

About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases. We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the estimated timing for preliminary data from ASPIRO, the potential of AT132 to be a transformative product for the treatment of XLMTM. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, obtain regulatory approval of and ultimately commercial its product candidates, the timing and results of preclinical and clinical trials, the company's ability to fund development activities and achieve development goals, the company's ability to protect intellectual property and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Audentes Contacts:

Investor Contact:
Andrew Chang
Director, Investor Relations
415.818.1033
ir@audentestx.com

Media Contact:
Paul Laland
415.519.6610
media@audentestx.com